Mitsubishi Gas Chemical Company, Inc. (MGC; Head Office: Chiyoda-ku, Tokyo; President: Masashi Fujii) hereby announces that it has signed a business collaboration agreement with Hokkaido System Science Co., Ltd. (HSS; Head Office: Sapporo, Hokkaido; President: Yukio Mizutani) to jointly study the feasibility of entering the nucleic acid drug CDMO (Contract Drug Development and Manufacturing) business.

MGC has set “medical/ food” as a target area in its medium-term management plan “Grow UP 2026” and is promoting a variety of related initiatives. These efforts come under the umbrella of MGC’S Key Issue (Materiality) “promotion of innovative R&D” which is part of Strategy 2 (Build new value through innovation) in Objective 1 (Strengthen the resiliency of our business portfolio) of the plan. The nucleic acid medicine market has future growth potential, and MGC will work alongside HSS to examine the feasibility of developing a CDMO business to add its antibody medicine CDMO business.

HSS has a proven track record in synthesizing and selling nucleic acids for use in research, and together with MGC’s analytical technology and knowledge of Good Manufacturing Practice (GMP), the two companies aim to launch a nucleic acid drug CDMO business that can provide meaningful solutions to stakeholders, including researchers in academia.

Note: The content of this press release has not been edited by Fibre2Fashion staff.

Fibre2Fashion News Desk (HU)